Condition
Essential Blepharospasm
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
100%
4 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 3 (2)
P 4 (2)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03641950Phase 4CompletedPrimary
The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.
NCT03216473Phase 3CompletedPrimary
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm
NCT01791881Phase 3CompletedPrimary
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm
NCT01259557Phase 4CompletedPrimary
Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm
Showing all 4 trials